-62.7%
IREN vs GSK
+8.8%
-71.4%
-73.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.7% | -0.4% | -6.3% | -7.1% |
| 7D | -16.0% | +0.2% | -16.3% | -15.8% |
| 30D | -40.5% | +5.4% | -45.9% | -37.1% |
| 3M | -59.4% | +0.9% | -60.3% | -58.0% |
| 6M | -67.1% | +0.7% | -67.8% | -65.7% |
| YTD | -51.9% | +5.6% | -57.5% | -40.6% |
| 1Y | -62.7% | +8.5% | -71.2% | -52.5% |
| All | -62.7% | +8.8% | -71.4% | -52.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling